RxDoctor Payments Data

Stuart Baird, MD

Interventional Pain Medicine · Las Vegas, NVNPI 1336383504

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Abbott at 40.5% of the total. Reporting peaked in 2019 at $914 and has fallen 63.6% since, to $333 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NV, where the typical reported total is $4,162.

$3,309in general payments, 2019–2025

Across 90 payments — averaging $36.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Nevro Corp.$762
  • Boston Scientific$380
  • Medtronic$268
  • Si-bone, Inc.$149
  • Scilex Pharmaceuticals Inc.$129
  • plus $280 from 8 others

What the payments were for

  • Food & beverage$3,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,309 in reported general payments places this provider in the 40th percentile of 32 interventional pain medicine providers in Nevada.

See all interventional pain medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$130,534
Medicare patients
175
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$646
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$578
Naproxen33$202
Tizanidine Hcl43$189
Gabapentin18$170

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →